AB-FUBINACA Crystal for sale online
What is AB-FUBINACA Crystal?
AB-FUBINACA is a designer drug that acts as a potent agonist for the cannabinoid receptors. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use.Buy AB-FUBINACA Crystal
Effects on humans are said to be ‘euphoric, stimulating high, increases creativity and appetite, also short term memory deficits, similar to Cannabis’ (PsychonautWiki).
3b. i. Pharmacology
AB-FUBINACA remains orally active when dissolved in a lipid, which can increase the duration significantly.
It is presumed from structural analysis that AB-FUBINACA has a similar binding profile to that of other synthetic cannabinoids and therefore has many of the in vivo properties of THC.
While THC is a partial agonist of the CB1 and CB2 receptors (inducing only partial efficacy), both AB-FUBINACA and AMB-FUBINACA exhibit their range of effects via full agonism of both the CB1 and CB2 receptors, with a lesser selectivity for CB2, therefore inducing a much stronger biological response (Mackie 2008). AB-FUBINACA exerts potent cannabimimetic effects (ie, having similar pharmacological effects to those of cannabis) on locomotion, body temperature, heart rate, and nociception in mice and rats, as well as substituting for THC in drug discrimination assays (Banister et al 2015, Gatch and Forster 2015).
Users have reported they experienced a very fast onset of action for AB-FUBINACA (within a minute), lasting up to about 45 minutes. User reports talked of ‘trippy’, ‘stoned’, ‘feeling heavy’, ‘feeling glowy’, euphoria and visuals. One user reported paranoia and incoherency. Effects are described as being mild to moderate for AB-FUBINACA at different dosages (see the dosage table in the Dosage section below), and very high doses elicit a stronger effect (Erowid.org website).
AB-FUBINACA was originally developed by Pfizer in 2009 as an analgesic. It was first reported in synthetic cannabis in Japan in 2012. It was found in Spice/K2-type herbal blends.